Swiss National Bank Has $264.70 Million Position in Boston Scientific Co. (NYSE:BSX)

Swiss National Bank cut its stake in Boston Scientific Co. (NYSE:BSX) by 1.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,578,700 shares of the medical equipment provider’s stock after selling 45,600 shares during the period. Swiss National Bank owned approximately 0.31% of Boston Scientific worth $264,695,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Victory Capital Management Inc. raised its position in Boston Scientific by 5.6% during the third quarter. Victory Capital Management Inc. now owns 518,047 shares of the medical equipment provider’s stock valued at $27,353,000 after purchasing an additional 27,620 shares in the last quarter. Louisiana State Employees Retirement System acquired a new position in Boston Scientific during the fourth quarter worth about $5,116,000. Glenmede Trust Co. NA lifted its holdings in shares of Boston Scientific by 12.1% in the third quarter. Glenmede Trust Co. NA now owns 10,442 shares of the medical equipment provider’s stock worth $551,000 after acquiring an additional 1,123 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of Boston Scientific by 2.1% in the 3rd quarter. Principal Financial Group Inc. now owns 1,868,991 shares of the medical equipment provider’s stock valued at $98,683,000 after purchasing an additional 38,249 shares in the last quarter. Finally, HealthInvest Partners AB acquired a new position in Boston Scientific during the 4th quarter worth approximately $3,746,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Up 1.2 %

Boston Scientific stock traded up $0.83 during trading on Friday, hitting $72.86. 7,452,079 shares of the company were exchanged, compared to its average volume of 6,661,660. The company has a current ratio of 1.32, a quick ratio of 0.82 and a debt-to-equity ratio of 0.44. The business’s 50 day moving average is $68.30 and its 200 day moving average is $61.11. Boston Scientific Co. has a 52 week low of $48.35 and a 52 week high of $74.39. The company has a market capitalization of $109.29 billion, a P/E ratio of 61.22, a PEG ratio of 2.48 and a beta of 0.77.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.51 by $0.04. Boston Scientific had a net margin of 12.06% and a return on equity of 16.63%. The company had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.59 billion. During the same period last year, the firm earned $0.45 earnings per share. Analysts predict that Boston Scientific Co. will post 2.32 earnings per share for the current year.

Analysts Set New Price Targets

BSX has been the topic of a number of research reports. Royal Bank of Canada upped their price target on shares of Boston Scientific from $78.00 to $82.00 and gave the stock an “outperform” rating in a report on Thursday, April 25th. StockNews.com cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 16th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Boston Scientific from $63.00 to $73.00 and gave the company a “hold” rating in a report on Thursday, April 25th. Robert W. Baird lifted their target price on shares of Boston Scientific from $79.00 to $84.00 and gave the stock an “outperform” rating in a research report on Thursday, April 25th. Finally, Oppenheimer raised their price target on shares of Boston Scientific from $58.00 to $68.00 and gave the company a “market perform” rating in a research note on Thursday, February 1st. Three analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.09.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward J. Ludwig sold 9,818 shares of Boston Scientific stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $73.29, for a total value of $719,561.22. Following the completion of the sale, the director now owns 41,374 shares of the company’s stock, valued at approximately $3,032,300.46. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Boston Scientific news, Director Edward J. Ludwig sold 9,818 shares of Boston Scientific stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $73.29, for a total transaction of $719,561.22. Following the completion of the transaction, the director now owns 41,374 shares of the company’s stock, valued at approximately $3,032,300.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total transaction of $467,092.87. Following the completion of the transaction, the executive vice president now owns 56,508 shares of the company’s stock, valued at $3,779,820.12. The disclosure for this sale can be found here. Insiders have sold a total of 78,384 shares of company stock worth $5,395,560 over the last three months. 0.50% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.